Home>Topics>Companies>Baxter International

Baxter International BAX

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. When Boring Becomes Exciting

      Headlines

      Mon, 15 Dec 2014

      the past quarter include: ABB Ltd., Ann Inc., Baxter International , International Game Technology, TRW Automotive ..... and is subject to change: ABB Ltd., Ann Inc., Baxter International , International Game Technolgy, TRW Automotive

    2. United States Anesthesia Drugs Market & Forecast

      Commentary

      Fri, 12 Dec 2014

      maximum market share. From companies analysis part Baxter International Inc , Endo Health Solutions Inc and Abbott Laboratories ..... Profile in United States Anesthetic Drugs Market Baxter International Inc Endo Health Solutions Inc Abbott Laboratories

    3. Finding a Margin of Safety in a Fully Valued Market

      Headlines

      Fri, 21 Nov 2014

      three firms that passed the screen: Baxter BAX Current Price: $72 | Fair Value ..... think diversified health-care firm Baxter has earned a wide economic moat ..... products. Intangible assets--like Baxter 's strong brands, patent protection

    4. Baxter's 3Q Reflects Hemophilia Competitive Advantages; Well-Positioned for Plasma and Renal Growth

      Commentary

      Thu, 16 Oct 2014

      value estimate for Baxter after third-quarter results. Baxter 's revenue (excluding the vaccine business, which ..... 32. Overall, Baxter 's hemophilia franchise ..... example, Baxalta ( Baxter 's BioScience spin-off ..... proteins. The new Baxter stands to benefit ..... Biosurgery and Specialty Pharmaceuticals .

    5. Health Care: Some Healthy Bargains Still Remain

      Headlines

      Wed, 1 Oct 2014

      Narrow Medium $39.90 Baxter $84.00 Wide Low $67 ..... stock look undervalued. Baxter BAX While competition is increasing for Advate, Baxter 's highly profitable hemophilia ..... Intangible assets--like Baxter 's strong brands, patent

    6. Baxter Remains Undervalued as BAX 855 Appears on Track for U.S. Launch in 2015

      Commentary

      Thu, 21 Aug 2014

      Baxter has reported positive ..... Phase III study of BAX 855, a twice-weekly ..... particularly given that BAX 855 is now one step ..... committee review of Baxter 's differentiated ..... for the stock. Baxter 's wide, stable ..... patients taking BAX 855 as a twice-weekly

    7. Baxter's Vaccine Business Lands at Pfizer; No Fair Value Changes

      Commentary

      Wed, 30 Jul 2014

      Baxter has announced the divestiture ..... will form the heart of Baxter 's biopharmaceutical ..... spin-off. We note that Baxter could also see a smaller sale of its vaccine technology, which ..... programs. We think Baxter remains undervalued

    8. The Friday Five

      Video Reports

      Fri, 18 Jul 2014

      manufacturing, the recall issues they had recently, so really pharmaceuticals are driving that story right now. Benz: So I know at ..... seeing a lot of value in those names. There's a few-- Baxter looks like it's probably pretty well-positioned right

      pharmaceuticals found at 5:32

      some issues in manufacturing, the recall issues they had recently, so really pharmaceuticals are driving that story right now. Benz: So I know at one point a few years ago all the pharma stocks looked pretty cheap to us, how about right now, especially J&J? Glaser: Yeah, let's keep this theme going. We just aren't seeing a lot of value in those names. There's a few-- Baxter looks like it's probably pretty well-positioned right now and looking relatively inexpensive--but there just aren't a huge number of values there. Benz:
    9. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns

      Headlines

      Thu, 26 Jun 2014

      leverage to nearly 5 times in order to acquire Cadence Pharmaceuticals . While the deal gives Mallinckrodt a new platform to ..... ZMH because of these events. Also, in early 2014, Baxter BAX "> BAX announced a plan to split into two entities next year

    10. Moats and Growth Drivers Look Solid for Post-Split Baxter

      Headlines

      Sun, 15 Jun 2014

      When Baxter BAX spins off its biopharmaceutical ..... putting pressure on the new Baxter to make the most of the integration ..... undeveloped market. With Gambro, Baxter was looking to diversify its ..... it quite complementary to Baxter . Given that the vast majority

    « Prev12345Next »
    Content Partners